Faldaprevir is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor. Faldaprevir is known to inhibit P-glycoprotein, CYP3A4, and UDP-glucuronosyltransferase 1A1. This study evaluated the effect of steady-state 240 mg faldaprevir on the pharmacokinetics (PK) of an oral contraceptive containing ethinylestradiol (EE) and levonorgestrel (LNG) in healthy premenopausal women. In period 1, subjects received EE/LNG once daily (QD) for 14 days. Blood samples were taken on days 1, 11, and 12, with intensive PK blood sampling for EE and LNG on day 13. In period 2, subjects received EE-LNG QD and 240 mg faldaprevir QD on days 14 to 21 (240 mg faldaprevir twice daily on day 14). Blood samples were taken on days 14, 19, and 20, with PK profiling samples obtained for EE and LNG on day 21. A total of 15/16 subjects completed the study. Overall, EE and LNG exposure (assessed by the area under the curve) was approximately 1.4-fold higher when EE and LNG were coadministered with faldaprevir than when administered alone. Median t 1/2 (terminal half-life in plasma at steady state) values were prolonged for both EE (2.4 h longer) and LNG (4.7 h longer) when EE and LNG were coadministered with faldaprevir. The mean oral clearance and apparent volume of distribution of both EE and LNG were lower (ϳ30%) when EE and LNG were coadministered with faldaprevir. Coadministration of faldaprevir and an oral contraceptive resulted in a moderate increase in exposure to both EE and LNG. However, this increase was not considered clinically meaningful, and no dose adjustment of oral contraceptives was deemed necessary. (This study has been registered at ClinicalTrials.gov under registration number NCT01570244.) C hronic hepatitis caused by hepatitis C virus (HCV) infection is the leading cause of liver cirrhosis and liver cancer and represents a major global health problem (1, 2). A combination of pegylated interferon (PegIFN) and ribavirin (RBV) was the standard HCV therapy until 2011, when the advent of the first HCV protease inhibitors (telaprevir and boceprevir) led to increased sustained virologic response (SVR) rates over this combination alone and demonstrated efficacy in patients who did not respond to PegIFN and RBV (3, 4) . However, the addition of protease inhibitors to the PegIFN and RBV treatment regimen led to an increase in side effects and a higher level of treatment discontinuation (4, 5). State-of-the-art treatment strategies for HCV are PegIFN free and are comprised of a combination of direct-acting antiviral agents; these newer protease inhibitors may offer wider antiviral activity and a greater barrier to resistance with improved safety profiles on a convenient dosing schedule (5).
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Faldaprevir (BI 201335; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT) is a potent HCV nonstructural 3/4A (NS3/4A) protease inhibitor, with in vitro antiviral activity against HCV genotypes 1 (GT-1), 4, 5, and 6 (6). Phase I and II studies have indicated that a once-daily (QD) dosing schedule of up to 240 mg faldaprevir in combination with PegIFN and RBV is well tolerated in patients with HCV GT-1 infection and results in a significant decrease in the viral load, suggesting strong antiviral activity (7) (8) (9) . The results from the phase III trial, STARTVerso1, in treatment-naive patients with HCV GT-1 infection (n ϭ 652) demonstrated an SVR 12 weeks after completion of treatment (SVR12) in 80% of patients who received 240 mg faldaprevir QD combined with PegIFN and RBV compared with 52% of patients who received PegIFN, RBV, and placebo (P Ͻ 0.0001) (10) .
A large proportion of female patients with HCV infection are of childbearing age (11) , and many may wish to take hormonal contraceptives or, if postmenopausal, could receive hormone replacement therapy. The availability of effective hormonal contraceptives or hormone replacement therapy that can be safely coadministered with direct-acting antiviral agents will allow these patients unrestricted access to HCV treatment. Hormonal contraceptives taken with HCV therapies are likely to contain synthetic estrogens (e.g., ethinylestradiol [EE] ) and progestogens (e.g., levonorgestrel [LNG] ). It is therefore important to assess the drug-drug interactions of antiviral therapies and synthetic hormones (12) . In vivo data suggest that with a twice-daily (BID) dose of 240 mg in healthy volunteers, faldaprevir is a weak inhibitor of CYP2C9 and a moderate inhibitor of CYP3A4 (13) , whereas a dose of 120 mg faldaprevir QD in HCV patients resulted in weak inhibition of CYP3A4 and had no effect on CYP2C9 (14) . In vitro data also suggest that faldaprevir inhibits P-glycoprotein (P-gp), UDP-glucuronosyltransferase (UGT1A1), and CYP2C8 (14, 15) . EE, which has a terminal half-life of 10 to 20 h, is metabolized in the liver by hydroxylation mediated by CYP3A4 and CYP2C9, followed by glucuronidation by UGT1A1 (12) . LNG is a substrate of CYP3A4 and is metabolized to sulfate and glucuronide conjugates, with a terminal half-life of 25 h (12, 16). As such, faldaprevir inhibition of CYP3A4, CYP2C9, or UGT1A1 may increase exposure to EE and LNG, while EE and LNG are not expected to affect faldaprevir metabolism by CYP3A4 (17) (18) (19) (20) .
The objective of this study was to evaluate the effect of 240 mg faldaprevir QD at steady state on the pharmacokinetics (PK) of a combined oral contraceptive containing 30 g EE and 150 g LNG in healthy premenopausal female volunteers.
MATERIALS AND METHODS

Trial design.
This was an open-label, two-period, fixed-sequence, phase I trial in 16 healthy premenopausal women aged 18 to 35 years with a body mass index (BMI) of 18.5 to 27 kg/m 2 . The subjects started with a run-in period (starting between days Ϫ56 and Ϫ28) and received 30 g EE-150 g LNG (1 tablet Microgynon; Bayer Pharma AG, Berlin, Germany) QD until day Ϫ8. No treatment was administered on days Ϫ7 to Ϫ1 to induce withdrawal bleeding. In period 1, the subjects received 30 g EE-150 g LNG QD on days 1 to 13; on the 14th day, the subjects proceeded directly to period 2, where they received 30 g EE-150 g LNG QD with a loading dose of 480 mg faldaprevir (240 mg BID) on day 14 and 240 mg faldaprevir QD on days 15 to 21. The end-of-study examination was performed 6 to 14 days after the end of period 2.
The study was conducted at Biberach, Germany, in accordance with the International Conference on Harmonisation guideline for good clinical practice and the principles of the Declaration of Helsinki and was reviewed and approved by the Independent Ethics Committee (EthikKommission der Landesärztekammer Baden-Württemberg, Stuttgart, Germany).
Pharmacokinetics evaluation. Blood samples were collected at predetermined time points for PK analyses. The concentrations of EE and LNG in plasma were determined by a validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method (Bioanalytical Systems Inc., West Lafayette, IN, USA), and linear calibration curves were obtained between 5 and 500 pg/ml for EE, with a lower limit of quantification (LLOQ) of 5 pg/ml, and between 0.1 and 10 ng/ml, with an LLOQ of 0.1 ng/ml, for LNG.
The primary PK parameters analyzed were the area under the plasma concentration-time curve at steady state over the uniform dosing interval , where is 24 h (AUC ,ss ), the maximum plasma concentration at steady state over the uniform dosing interval (C max,ss ), and the plasma concentration at the end of the uniform dosing interval (C 24,ss ). Other PK parameters of interest were the time to reach C max at steady state (t max,ss ), the terminal half-life in plasma at steady state (t 1/2 ), the plasma clearance following administration at steady state (CL/F ss ), and the volume distribution during the terminal phase z at steady state following administration (Vz/F ss ).
Safety and tolerability. Adverse-event (AE) data, 12-lead electrocardiograms (ECGs), blood pressure, pulse rate, physical examinations, and laboratory safety assessments were collected to assess the safety and tolerability of faldaprevir when given concomitantly with EE and LNG. All subjects who received at least one dose of trial medication were included in the safety analyses.
Statistical analysis. To assess the drug interaction potential, twosided 90% confidence intervals (CIs) for the geometric mean (gmean) ratios at steady state were calculated for the AUC ,ss , C max,ss , and C 24,ss of EE and LNG and assessed by mixed-effects analysis of variance (ANOVA) on a logarithmic scale. The primary analysis was based on the PK analysis set including all subjects in the treated set who provided evaluable data from at least one observation for at least one PK endpoint. Descriptive statistics were used to analyze all other parameters. Compliance and the attainment of steady state were investigated using predose trough concentrations for EE and LNG on days 11, 12, and 13 in period 1 and EE, LNG, and faldaprevir on days 19, 20, and 21 in period 2 and assessed using a repeated-measures ANOVA. None of the subjects reported any relevant medical history or baseline conditions; concomitant therapies were reported by 12/16 subjects (75.0%), of whom 8 (50.0%) had taken oral contraceptives, 4 (25.0%) reported intake of ibuprofen, and 2 (12.5%) had taken dimenhydrinate.
RESULTS
Subject
Pharmacokinetics. After the 7-day treatment-free period, EE was not detectable in any plasma samples from the subjects, while in 6 subjects, LNG concentrations were above the LLOQ; however, as the concentration did not exceed 5% of the C max,ss for these subjects, the data were included in the analysis. Steady state was achieved by EE and LNG in period 1 and by EE, LNG, and faldaprevir in period 2 as assessed by comparing gmean trough concentrations on days 6, 7, and 8 and days 19, 20 . Following administration of 30 g EE-150 g LNG QD in period 1, the concentrations of both hormones in plasma rose rapidly, reaching C max,ss within 2 h; in period 2, higher trough concentrations and slightly higher maximum exposure were observed for EE and LNG when coadministered with faldaprevir ( Fig. 1 and 2 ). Individual and gmean AUC ,ss , C max,ss , and C 24,ss for EE and LNG at steady state when administered alone and in combination with faldaprevir are shown in Fig. 3 . Increases in the EE gmean AUC ,ss from 1,010 pg · h/ml to 1,450 pg · h/ml and in the gmean C max,ss from 108 pg/ml to 127 pg/ml were observed when EE was coadministered with faldaprevir. A similar increase in LNG plasma concentrations were seen when LNG was coad-ministered with faldaprevir: gmean AUC ,ss from 83.3 ng · h/ml to 120 ng · h/ml and gmean C max,ss from 7.57 ng/ml to 8.95 ng/ml. Increases in trough concentrations of EE (C 24,ss , 19.1 pg/ml to 33.2 pg/ml) and LNG (C 24,ss , 2.43 ng/ml to 3.85 ng/ ml) were observed when EE and LNG were coadministered with faldaprevir. Comparison of total and peak exposures of EE and LNG when coadministered with faldaprevir compared with hormone administration alone was analyzed by the gmean ratios (GMR). The approximate GMR for AUC ,ss was 140% for both EE and LNG, and the C max,ss was approximately 115% for both hormones, while the C 24,ss was 171.4% for EE and 153.9% for LNG ( Table 1 ).
The time taken for EE and LNG to reach C max,ss (t max ) at steady state did not increase with coadministration of faldaprevir, while median t 1/2 values increased by 3.0 h for EE and 10.8 h for LNG (Table 1) . A lower mean oral clearance and apparent volume of distribution for EE and LNG were seen for EE and LNG when 
FIG 3
Individual and gmean AUC ,ss , C max,ss , and C 24,ss for EE (AUC ,ss , pg · h/ml; C max,ss and C 24,ss , pg/ml) and LNG (AUC ,ss , ng · h/ml; C max,ss and C 24,ss , ng/ml) at steady state when administered alone and in combination with faldaprevir.
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coadministered with faldaprevir than with EE and LNG administered alone (Table 1) . Adverse events. In period 1, all 16 subjects received all the planned doses of EE and LNG, while in period 2, 15 of the 16 subjects received all doses of EE, LNG, and faldaprevir. One subject discontinued treatment on day 18 (period 2) due to an AE of recurrent moderate nausea and therefore received 5 of the 8 planned doses of EE and LNG and 6 of the 9 doses of faldaprevir.
AEs were reported by 12/16 subjects (75.0%) in period 1 and all patients (16/16) in period 2, and most were mild or moderate in severity (Table 2 ). There were no deaths, serious AEs, or significant prespecified AEs (hepatic injury) reported.
In period 1 (EE plus LNG), AEs belonging to the nervous system organ class were the most frequently reported (7 subjects; 43.8%), with headache being the most reported event (5 subjects; 31.3%). Gastrointestinal disorders, infections and infestations, and musculoskeletal and connective tissue disorders were all reported in 2/16 subjects each (12.5%). Details of the AEs are provided in Table S1 in the supplemental material.
In period 2 (EE plus LNG plus faldaprevir), AEs belonging to the gastrointestinal system organ class were the most frequently reported (12 subjects; 75.0%), including nausea (8 subjects; 50.0%); abdominal discomfort or vomiting (4 subjects; 25.0% each reported); diarrhea (2 subjects; 12.5%); and upper abdominal pain, stomatitis, or flatulence (each reported by 1 subject). One subject experienced severe diarrhea and nausea, which led to the subject withdrawing from the trial, and 3 subjects experienced treatment-related severe nausea. The second most frequently reported system organ class was nervous system disorders in 8/16 subjects (50.0%), with headache in 6 subjects (37.5%) and dizziness in 3 subjects (18.8%) being the most common.
Fifteen subjects had increased bilirubin levels after the addition of faldaprevir, and in 6 subjects, this was associated with mild ocular icterus. The increase in total bilirubin was due primarily to increases in indirect bilirubin, a predicted effect of faldaprevir due to inhibition of UGT1A1 and hepatic uptake transporters. In all cases, the increase in bilirubin was Ͻ5 times the upper limit of normal (ULN) and generally returned to normal levels after completion of faldaprevir dosing (for 4 subjects, the elevated bilirubin concentrations were decreasing but had not reached the normal range prior to the end of the trial). The increase in bilirubin was not associated with increases in alanine transaminase, aspartate transaminase, or gamma glutamyl transpeptidase. No other relevant changes in laboratory parameters were observed, apart from small increases in creatinine levels in 7 subjects.
DISCUSSION
Coadministration of faldaprevir and an oral contraceptive agent containing EE and LNG resulted in a modest or moderate increase in exposure to EE and LNG in healthy premenopausal women. Given the safety profile of hormonal oral contraceptives, these changes in EE and LNG exposure are not considered clinically important. The observed increase in the C 24,ss and t 1/2 of EE/LNG after coadministration with faldaprevir suggests that the elimination phase of EE/LNG was altered, consistent with either CYP3A4 or UGT1A1 inhibition. In vitro data have shown that CYP3A4 is one of the key enzymes involved in EE/LNG oxidative metabolism in the liver (21) , and thus, a likely mechanism for the increased exposure is via altered EE elimination due to the inhibition of CYP3A4 by faldaprevir. Inhibition of UGT1A1 by faldaprevir, reported by Sane and colleagues (15) , may affect glucuronidation of synthetic hormones in the liver and could contribute to the increased exposure of EE and LNG reported here.
Studies of other HCV therapies in combination with oral contraceptives have also demonstrated alterations in exposure to the synthetic hormone components. When telaprevir was coadministered with an oral contraceptive containing EE, a reduction of 26% in the AUC and 33% in the C min (the minimum concentration of a drug after its administration and just prior to the administration of a subsequent dose) for EE was reported, which may result in reduced contraceptive efficiency (20) . Coadministration of an oral contraceptive and the protease inhibitor boceprevir (a strong inhibitor of CYP3A4) resulted in reductions in the EE AUC and C max of 26% and 21%, respectively, but this was considered unlikely to alter contraceptive effectiveness (22) . As EE is a potential substrate of P-gp (23) and faldaprevir is known to be an inhibitor of P-gp, interaction of the efflux transporter P-gp may also contribute to the observed increased exposure of EE.
One potential limitation of the study was that all the subjects enrolled in the study were young Caucasian females. The selection of this population was not the intention of the study design but rather the result of random screening of a small sample size (n ϭ 16), which does not fully represent the patient population with HCV infection (11) . As the study was a crossover design, any age and race effect on the metabolism of oral contraceptives would occur during both treatments (with and without faldaprevir), and thus, it is expected that any effect would be minimized. Given the fact that oral contraceptives containing EE/LNG are expected to be taken by premenopausal women who are relatively young, it is not expected that age would have a clinically meaningful effect on their exposure/metabolism (24) . There are reports in the literature of a small, but not clinically meaningful, effect of ethnicity on the activity of CYP3A4 (25) , an enzyme responsible for the majority (Ͼ67%) of EE/LNG metabolism (12, 16) ; a pooled PK analysis of EE exposure confirmed that a race effect on EE exposure was indeed not (clinically) significant (24) . Taking the data together, we conclude that the observed drug-drug interaction between faldaprevir and EE/LNG can be applied to other populations who take EE/LNG as oral contraceptives. The majority of observed AEs were seen in the period of coadministration and are consistent with the known safety profile of faldaprevir (7, 8) ; headache, a commonly reported AE with oral contraceptives (16) , was reported similarly in the period with oral contraceptive administration alone and when coadministered with faldaprevir. Increases in bilirubin concentrations with the 240-mg faldaprevir QD dose were predominantly unconjugated, reversible, and not associated with markers of liver injury. These transient increases in indirect bilirubin occur due to inhibition of UGT1A1 and hepatic transporters and are a well-known effect of treatment with faldaprevir (15) . Phase II and III studies have demonstrated that these reversible increases in indirect bilirubin occur in the absence of increases in other markers of liver injury, and they are not considered clinically significant (15, 26, 27) .
In the faldaprevir phase III study program, due to the concomitant use of ribavirin, women of childbearing potential were asked to use barrier methods of contraception throughout the duration of the study; however, some patients also used oral contraceptives. Analysis of the safety profiles of female patients who received faldaprevir showed similar number of AEs in those who took concomitant oral contraceptives and those who did not (Boehringer Ingelheim, data on file).
In conclusion, a moderate but not clinically meaningful effect on EE and LNG exposure was observed with coadministration of a combination of oral contraceptives and faldaprevir in healthy premenopausal women. The safety profile reported in this trial was consistent with that reported in previous studies on faldaprevir. These data indicate that faldaprevir can be safely coadministered with oral contraceptives containing EE and LNG and that dose adjustment of oral contraceptives is not necessary.
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